Roivant Sciences (ROIV) Retained Earnings (2021 - 2026)
Roivant Sciences (ROIV) posted Retained Earnings of -$501.8 million for Q1 2026, down 110.15% on a QoQ basis from $4.9 billion in Q4 2025, and down 111.0% year-over-year from $4.6 billion in Q1 2025.
Roivant Sciences (ROIV) Retained Earnings (2021 - 2026) Analysis & Trends
Roivant Sciences' Retained Earnings history runs 6 years deep, the most recent figure standing at -$501.8 million for Q1 2026.
- Quarterly Retained Earnings fell 111.0% year-over-year to -$501.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501.8 million (down 111.0% YoY) and the FY2026 annual result came in at -$501.8 million, down 111.0% from the prior year.
- Retained Earnings was -$501.8 million for Q1 2026 at Roivant Sciences, down from $4.9 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $5.4 billion in Q4 2023 and bottomed at -$4.4 billion in Q3 2023.
- A 5-year average of $615.6 million and a median of $17.1 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 305894.05% — and 2025, when it tumbled 208.48%.
- Roivant Sciences' Retained Earnings stood at -$3.7 billion in 2022, then soared by 245.68% to $5.4 billion in 2023, then decreased by 12.42% to $4.7 billion in 2024, then grew by 4.72% to $4.9 billion in 2025, then tumbled by 110.15% to -$501.8 million in 2026.
- Business Quant data shows ROIV's Retained Earnings at -$501.8 million in Q1 2026, $4.9 billion in Q4 2025, and -$429.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | -501.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -501.81 Mn |
| Dec 31, 2025 | 4.94 Bn |
| Sep 30, 2025 | -429.11 Mn |
| Jun 30, 2025 | 17.14 Mn |
| Mar 31, 2025 | 4.56 Bn |
| Dec 31, 2024 | 4.72 Bn |
| Sep 30, 2024 | 395.58 Mn |
| Jun 30, 2024 | 671.50 Mn |
| Mar 31, 2024 | -4.08 Mn |
| Dec 31, 2023 | 5.39 Bn |
| Sep 30, 2023 | -4.37 Bn |
| Jun 30, 2023 | -4.10 Bn |
| Mar 31, 2023 | 4.93 Bn |
| Dec 31, 2022 | -3.70 Bn |
| Sep 30, 2022 | -3.39 Bn |
| Jun 30, 2022 | -3.10 Bn |
| Mar 31, 2022 | 4.42 Bn |
| Dec 31, 2021 | 4.36 Bn |
| Sep 30, 2021 | 4.25 Bn |
| Jun 30, 2021 | 3.82 Bn |